Findings

What do systematic reviews say?

38 questions · 38 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 15.8%GRADE not reported 0 · 0%Very low 16 · 42.1%Low 8 · 21.1%Moderate 8 · 21.1%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Antiplatelet therapy vs placebo · Incident dementia
  Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Antiplatelet drug vs placebo · Change in cognitive function from baseline
  Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 280 participants
  Very low
Direct match · question page
- Antiplatelet therapy vs placebo · Change in cognitive function from baseline
  Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Very low
Direct match · question page
- Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy · Intracerebral haemorrhage (ICH)
  Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  RR 0.52 [0.27, 1.03]
  1 study · 536 participants
  Moderate
Direct match · question page
- Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy · All major occlusive vascular events
  Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  RR 1.03 [0.68, 1.55]
  1 study · 536 participants
  Moderate

Dual antiplatelet therapy vs one antiplatelet agent

Cognitive function · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3020 participants
Low

Dual antiplatelet therapy vs one antiplatelet agent

Incidence of dementia · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual antiplatelet therapy vs one antiplatelet agent

Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3020 participants
Low

Dual antiplatelet therapy vs one antiplatelet agent

Functional ability · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual antiplatelet therapy vs one antiplatelet agent

Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3020 participants
Low

Dual antiplatelet therapy vs one antiplatelet agent

Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dual antiplatelet therapy vs one antiplatelet agent

Withdrawal from study medication · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 3020 participants
Low

Antiplatelet therapy vs placebo

Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antiplatelet therapy vs placebo

Functional ability · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Withdrawal from study medication · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Cognitive function · people with cerebral small vessel disease and no dementia

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Very low

Antiplatelet therapy vs placebo

Incidence of dementia · people with cerebral small vessel disease and no dementia

The review found no eligible studies for this question.

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

MACE · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in MACE compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
RR 0.89 [0.64, 1.22]
1 study · 536 participants
Moderate

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Death · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in death compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
RR 1.08 [0.76, 1.53]
1 study · 536 participants
Moderate

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in all major occlusive vascular events compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
RR 1.03 [0.68, 1.55]
1 study · 536 participants
Moderate

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in intracerebral haemorrhage (ICH) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
RR 0.52 [0.27, 1.03]
1 study · 536 participants
Moderate

Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy

Functional outcomes · survivors of stroke due to intracerebral haemorrhage

Summary of findings table ‐ Starting long‐term oral antiplatelet… showed no clear difference in fnctional status (mRS 0‐2) compared with avoiding antithrombotic therapy (moderate certainty).

1 finding from 1 review

Antithrombotic treatment after stroke due to intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
RR 0.95 [0.77, 1.18]
1 study · 461 participants
Moderate

Antiplatelet drug vs placebo

Cognitive function · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…

1 finding from 1 review

Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 280 participants
Very low